Efficacy and safety of laparoscopic radical resection following neoadjuvant therapy for pancreatic ductal adenocarcinoma: A retrospective study

被引:1
|
作者
He, Yong-Gang [1 ]
Huang, Xiao-Bing [1 ]
Li, Yu-Ming [1 ]
Li, Jing [1 ]
Peng, Xue-Hui [1 ]
Huang, Wen [1 ]
Tang, Yi-Chen [1 ]
Zheng, Lu [1 ,2 ]
机构
[1] Army Med Univ, Dept Hepatobiliary, Affiliated Hosp 2, Chongqing 400037, Peoples R China
[2] Army Med Univ, Dept Hepatobiliary, Affiliated Hosp 2, 183 Xinqiao High St, Chongqing 400037, Peoples R China
关键词
Pancreatic ductal adenocarcinoma; Neoadjuvant chemotherapy; Laparoscopic pancreaticoduodenectomy; Laparoscopic radical antegrade modular pancreatosplenectomy; Complications; INTERNATIONAL STUDY-GROUP; UPFRONT RESECTION; CANCER; PANCREATICODUODENECTOMY; DEFINITION; SURGERY; TUMORS;
D O I
10.4251/wjgo.v14.i9.1785
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND Multiple studies have demonstrated that neoadjuvant chemotherapy (NACT) can prolong the overall survival of pancreatic ductal adenocarcinoma (PDAC) patients. However, most studies have focused on open surgery following NACT. AIM To investigate the efficacy and safety of laparoscopic radical resection following NACT for PDAC. METHODS We retrospectively analyzed the clinical data of 15 patients with pathologically confirmed PDAC who received NACT followed by laparoscopic radical surgery in our hospital from December 2019 to April 2022. All patients underwent abdominal contrast-enhanced computed tomography (CT) and positron emission tomography-CT before surgery to accurately assess tumor stage and exclude distant metastasis. RESULTS All 15 patients with pancreatic cancer were successfully converted to surgical resection after NACT, including 8 patients with pancreatic head cancer and 7 patients with pancreatic body and tail cancer. Among them, 13 patients received the nab-paclitaxel plus gemcitabine regimen (gemcitabine 1000 mg/m(2) plus nab-paclitaxel 125 mg/m(2) on days 1, 8, and 15 every 4 wk) and 2 patients received the modified FOLFIRINOX regimen (intravenous oxaliplatin 68 mg/m(2), irinotecan 135 mg/m(2), and leucovorin 400 mg/m(2) on day 1 and fluorouracil 400 mg/m(2) on day 1, followed by 46-h continuous infusion of fluorouracil 2400 mg/m(2)). After each treatment cycle, abdominal CT, tumor markers, and circulating tumor cell counts were reviewed to evaluate the treatment efficacy. All 15 patients achieved partial remission. The surgical procedures included laparoscopic pancreaticoduodenectomy (LPD, n = 8) and laparoscopic radical antegrade modular pancreatosplenectomy (L-RAMPS, n = 7). None of them were converted to a laparotomy. One patient with pancreatic head carcinoma was found to have portal vein involvement during the operation, and LPD combined with vascular resection and reconstruction was performed. The amount of blood loss and operation times of L-RAMPS vs LPD were 435.71 +/- 32.37 mL vs 343.75 +/- 145.01 mL and 272.52 +/- 49.14 min vs 444.38 +/- 68.63 min, respectively. The number of dissected lymph nodes was 16.87 +/- 4.10, and 3 patients had positive lymph nodes. One patient developed grade B postoperative pancreatic fistula (POPF) after L-RAMPS, and one patient experienced jaundice after LPD. None of the patients died after surgery. As of April 2022, progressive disease was noted in 4 patients, 2 patients had liver metastasis, and one had both liver metastasis and lymph node metastasis and died during the follow-up period. CONCLUSION Laparoscopic radical resection of PDAC after NACT is safe and effective if it is performed by a surgeon with rich experience in LPD and in a large center of pancreatic surgery.
引用
收藏
页码:1785 / 1797
页数:13
相关论文
共 50 条
  • [21] The Role of Neoadjuvant Therapy in Early Stage Pancreatic Ductal Adenocarcinoma: An NCDB Study
    Riachi, Mansour E.
    Kaslow, Sarah R.
    Kroon, Victor J.
    Habib, Joseph R.
    Cohen, Steven M.
    Simeone, Diane
    Welling, Theodore
    Shah, Paresh C.
    Griesemer, Adam
    Halazun, Karim
    Wolfgang, Christopher L.
    Hewitt, Daniel B.
    Sacks, Greg D.
    Javed, Ammar A.
    ANNALS OF SURGICAL ONCOLOGY, 2023, 30 (SUPPL 1) : S240 - S240
  • [22] Successful Resection After Neoadjuvant Therapy in Pancreatic Adenocarcinoma
    Peddi, Parvin F.
    Wang-Gillam, Andrea
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2012, 10 (11): : 1330 - 1334
  • [23] Neoadjuvant therapy for Non-metastatic Pancreatic Ductal Adenocarcinoma
    Winner, Megan
    Goff, Stephanie L.
    Chabot, John A.
    SEMINARS IN ONCOLOGY, 2015, 42 (01) : 86 - 97
  • [24] Best Practices for Delivering Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma
    Cloyd, Jordan M.
    Sarna, Angela
    Arango, Matthew J.
    Bates, Susan E.
    Bhutani, Manoop S.
    Bloomston, Mark
    Chung, Vincent
    Dotan, Efrat
    Ferrone, Cristina R.
    Gambino, Patricia F.
    Goenka, Ajit H.
    Goodman, Karyn A.
    Hall, William A.
    He, Jin
    Hogg, Melissa E.
    Jayaraman, Shiva
    Kambadakone, Avinash
    Katz, Matthew H. G.
    Khorana, Alok A.
    Ko, Andrew H.
    Koay, Eugene J.
    Kooby, David A.
    Krishna, Somashekar G.
    Larsson, Liliana K.
    Lee, Richard T.
    Maitra, Anirban
    Massarweh, Nader N.
    Mikhail, Sameh
    Muzaffar, Mahvish
    O'Reilly, Eileen M.
    Palta, Manisha
    Petzel, Maria Q. B.
    Philip, Philip A.
    Reyngold, Marsha
    Santa Mina, Daniel
    Sohal, Davendra P. S.
    Sundaresan, Tilak K.
    Tsai, Susan
    Turner, Kea L.
    Vreeland, Timothy J.
    Walston, Steve
    Washington, M. Kay
    Williams, Terence M.
    Wo, Jennifer Y.
    Snyder, Rebecca A.
    JAMA SURGERY, 2025, 160 (02) : 172 - 180
  • [25] PATIENT STATED PREFERENCES FOR NEOADJUVANT THERAPY IN PANCREATIC DUCTAL ADENOCARCINOMA
    Cloyd, Jordan
    Tsung, Allan
    Ejaz, Aslam
    Pawlik, Timothy M.
    Sarna, Angela
    Santry, Heena P.
    Wills, Celia
    Crossnohere, Norah
    GASTROENTEROLOGY, 2021, 160 (06) : S903 - S904
  • [26] Pancreatic ductal adenocarcinoma after neoadjuvant therapy: Histomorphologic characterisation
    Haeberle, L.
    Kapp, A. -C.
    Esposito, I.
    VIRCHOWS ARCHIV, 2017, 471 : S130 - S130
  • [27] Neoadjuvant therapy in pancreatic ductal adenocarcinoma: A competing risk analysis
    Pacilio, Carlo Alberto
    Grassi, Elisa
    Gardini, Andrea
    Fappiano, Francesca
    Passardi, Alessandro
    Frassineti, Giovanni Luca
    Tamberi, Stefano
    Ercolani, Giorgio
    SURGICAL PRACTICE, 2022, 26 (03) : 155 - 164
  • [28] Disparities in the Use of Neoadjuvant Therapy for Resectable Pancreatic Ductal Adenocarcinoma
    Cloyd, Jordan M.
    Shen, Chengli
    Santry, Heena
    Bridges, John
    Dillhoff, Mary
    Ejaz, Aslam
    Pawlik, Timothy M.
    Tsung, Allan
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2020, 18 (05): : 556 - +
  • [29] Biochemical Predictors of Response to Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma
    Awad, Seifeldin
    Alkashash, Ahmad M.
    Amin, Magi
    Baker, Samantha J.
    Rose, J. Bart
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [30] Surgical resection rates after neoadjuvant therapy for localized pancreatic ductal adenocarcinoma: meta-analysis
    Brown, Zachary J.
    Heh, Victor
    Labiner, Hanna E.
    Brock, Guy N.
    Ejaz, Aslam
    Dillhoff, Mary
    Tsung, Allan
    Pawlik, Timothy M.
    Cloyd, Jordan M.
    BRITISH JOURNAL OF SURGERY, 2023, 110 (01) : 34 - 42